Global Briefs: AbbVie, Nimble Therapeutics & Juncell
A roundup of news from AbbVie/Nimble Therapeutics and Juncell Therapeutics. Highlights below.
Mfg News
* Juncell Therapeutics Opens New Mfg Facility in China
M&A News
* AbbVie To Acquire Nimble Therapeutics for $200 M
Mfg News
Juncell Therapeutics Opens New Mfg Facility in China
Juncell Therapeutics, a Shanghai-based clinical-stage bio/pharmaceutical company, has opened a manufacturing facility in Shanghai, China for producing its IL-2-independent tumor-infiltrating lymphocyte (TIL) therapies for the treatment of solid tumors. The new facility, with a total area exceeding 16,000 square meters, houses the company’s production center, quality center, data center, and operation center. This facility has the capacity for TIL products for 6,000-10,000 patients annually. The company made the announcement last month (December 18, 2024).
Source: Juncell Therapeutics
M&A News
AbbVie To Acquire Nimble Therapeutics for $200 M
AbbVie has agreed to acquire Nimble Therapeutics, a Madison, Wisconsin-based bio/pharmaceutical company, for $200 million. The companies announced the deal last month (December 13, 2024).
Nimble’s lead asset is an investigational oral peptide IL23R inhibitor in preclinical development for the treatment of psoriasis. The company also has a pipeline of other oral peptide candidates with potential across several autoimmune diseases. AbbVie will also acquire Nimble’s peptide synthesis, screening, and optimization platform, which uses proprietary technology to help drive rapid discovery and optimization of peptide candidates for a range of targets.
Under the agreement, AbbVie will make a cash payment of $200 million at closing to acquire Nimble, subject to certain customary adjustments, in addition to certain interim funding payments. Nimble’s shareholders remain eligible for a potential payment, subject to the achievement of a development milestone. The transaction is subject to the satisfaction of customary closing conditions, including the applicable waiting period under the Hart-Scott- Rodino Antitrust Improvements Act.
Source: Nimble Therapeutics
